Structure Therapeutics (NASDAQ:GPCR) Trading Down 7.6% – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price fell 7.6% during trading on Monday . The company traded as low as $18.14 and last traded at $18.28. 27,802 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 840,175 shares. The stock had previously closed at $19.77.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. William Blair initiated coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Finally, JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Down 11.1 %

The stock has a market cap of $1.01 billion, a P/E ratio of -23.88 and a beta of -2.37. The firm’s 50-day moving average is $24.19 and its two-hundred day moving average is $31.16.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $3,091,000. GF Fund Management CO. LTD. bought a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $34,000. Woodline Partners LP lifted its stake in shares of Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock worth $9,055,000 after buying an additional 2,328 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of Structure Therapeutics by 50.0% in the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after buying an additional 575,000 shares during the last quarter. Finally, Twinbeech Capital LP boosted its holdings in shares of Structure Therapeutics by 34.3% during the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after buying an additional 7,220 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.